Navigation Links
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
Date:1/3/2011

CLEVELAND, Jan. 3, 2011 /PRNewswire/ -- Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).  JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death.  The new trial builds on the JVS-100 cardiovascular program that includes a U.S. Phase I heart failure (HF) clinical trial for which the Company recently completed enrollment of 17 patients.

"Juventas is excited to extend its clinical pipeline to include treatment of patients with CLI," stated Rahul Aras, Ph.D., President & CEO for Juventas Therapeutics.  "With our heart failure and critical limb ischemia programs moving into mid-stage clinical trials, the Company is focused on leveraging its regenerative medicine platform to address a range of cardiovascular indications with the goal of providing novel therapies to patients with limited options."

The randomized, placebo-controlled study will evaluate the efficacy and safety of JVS-100 in 48 patients (36 JVS-100 treated; 12 placebo) with Rutherford Class IV or V CLI.  The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), Ankle-Brachial Index (ABI) and ulcer closure.  

"Critical limb ischemia is a devastating disease for which there is currently no FDA-approved drug for treatment," said Douglas Losordo, M.D., Principal Investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University Feinberg S
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
2. Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
3. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
4. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
5. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
6. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
7. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Offering a complete line of laboratory ... promotion . The Sartorius Entris Balance is the perfect ... and easy-to-maintain balance entry level balance. , The Entris ... to help customer’s bridge the gap between a basic ... very durable. Sartorius is the second biggest balance manufacturer ...
(Date:11/21/2014)... Alto, Calif. (PRWEB) November 20, 2014 ... a nonprofit, public policy research organization representing leading ... pharmaceutical firms, and PwC US today ... states in life sciences industry growth. The trend ... 2013. The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... York, NY (PRWEB) November 20, 2014 ... is now available as an open access journal featuring ... with infrared fluorescent proteins to preserve photoresponsiveness in the ... Two-color fluorescent in situ hybridization using chromogenic substrates ... chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... Why did Stephen Hawking become so famous? ... recognizable? Why have they become icons to rival film ... Ratcliffe seeks out the answers to those questions, and ... with science. In " Stephen Hawking Smoked My Socks ... Ratcliffe puts it plainly: , “It is profoundly ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... Cambridge, Mass. - February 23, 2012 Engineers at Harvard ... uses optical nanoantennas to obtain precise control of color output. ... fixed color, a single active filter under exposure to different ... The advance has the potential for application in televisions and ...
... and AMSTERDAM, Feb. 23, 2012   Rubicon Genomics, ... pre-analytical processes to improve the capabilities and ... today announced a clinical supply agreement with ... whole genome RNA amplification technology.  Agendia will ...
... Study results published today in the   New - ...   show that 3-year graft survival is significantly greater in all ...   Kidney Transporter compared to those stored in a traditional box ... [1]   The graft survival difference at three years was ...
Cached Biology Technology:Metal nanoparticles shine with customizable color 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 2Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 3
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
... Dr. Jack Musick, emeritus professor at the Virginia Institute ... that 33 percent of shark, skate, and ray species ... of a major new study of vertebrates by the ... oldest and largest environmental network. The IUCN study shows ...
... This release is available in Spanish . ... are helping ensure that the smoked salmon that,s always a ... including among their achievements the development of a first-of-its-kind mathematical ... the optimal combination of temperature and concentrations of salt and ...
... of Texas Health Science Center at Houston (UTHealth) and ... to boost services to biomedical entrepreneurs and new bio-tech ... by executives for the two nonprofits calls for greater ... to promote services. "We saw the opportunity to ...
Cached Biology News:Study suggests a third of shark and ray species are threatened 2Study suggests a third of shark and ray species are threatened 3USDA scientists helping keep in-demand smoked salmon safe to eat 2UTHealth, BioHouston sign collaborative agreement 2
Immunochemistry 1 & 2...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
... The 1-D PAGE Cleavable ... for Targeted Protein ID ... PolyAcrylamide Gel Electrophoresis (PAGE), ... and cleavable-linker technology to ...
Antibody Purification Specificity: Antibody Purification ...
Biology Products: